High serum iron is associated with increased cancer risk

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6589-6597

  Wen, Chi Pang ^a,b   Lee, June Han ^a   Tai, Ya Ping ^a   Wen, Christopher ^c   Wu, Shiuan Be ^a   Tsai, Min Kuang ^a   Hsieh, Dennis P H ^a,d   Chiang, Hung Che ^a   Hsiung, Chao Agnes ^a   Hsu, Chung Y ^e   Wu, Xifeng ^f  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; DRINKING; FEMALE; HEPATITIS B VIRUS; HUMAN; IRON BLOOD LEVEL; LIFESTYLE; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; TAIWAN; YOUNG ADULT; BLOOD; NEOPLASMS; PROPORTIONAL HAZARDS MODEL; RISK;

ADULT; FEMALE; HUMANS; IRON; LIFE STYLE; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 84918575261     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0360     Document Type: Article

References (39)

1. Gaur A, Collins H, Wulaningsih W, Holmberg L, Garmo H, Hammar N, et al. Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer Causes Control 2013;24:1393-402.
2. Cross AJ, Sinha R, Wood RJ, Xue X, Huang WY, Yeager M, et al. Iron homeostasis and distal colorectal adenoma risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Prev Res 2011;4:1465-75.
3. Wells BJ, Mainous AG III, Everett CJ, Gill JM. Iron, cholesterol, and the risk of cancer in an 18-year cohort. Asian Pac J Cancer Prev 2005;6:505-9.
4. Ali MA, Akhmedkhanov A, Zeleniuch-Jaquotte A, Toniolo P, Frenkel K, Huang X. Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women. Cancer Detect Prev 2003;27:116-21.
5. Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-82.
6. Mainous AG III, Wells BJ, Koopman RJ, Everett CJ, Gill JM. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. Am J Epidemiol 2005;161:1115-22.
7. Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195-201.
8. Wurzelmann JI, Silver A, Schreinemachers DM, Sandler RS, Everson RB. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1996;5:503-7.
9. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
10. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127:S79-86.
11. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with noniron-related chronic liver disease. Hepatology 2001;33:647-51.
12. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF Jr. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160-2.
13. Foy SP, Labhasetwar V. Oh the irony: iron as a cancer cause or cure? Biomaterials 2011;32:9155-8.
14. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer science 2009;100:9-16.
15. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199-211.
16. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutation research 2003;533:153-71.
17. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-66.
18. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. Allcause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371:2173-82.
19. Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2011;378:1244-53.
20. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005;20:575-9.
21. Wen CP, Tsai SP, Chen CJ, Cheng TY. The mortality risks of smokers in Taiwan: part I: cause-specific mortality. Prev Med 2004;39:528-35.
22. Wen CP, David Cheng TY, Tsai SP, Chan HT, Hsu HL, Hsu CC, et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr 2009;12:497-506.
23. National Health and Nutrition Examination Survey. [cited 2013 July, 18]; Available from: http://www.cdc.gov/nchs/nhanes.htm.
24. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996;16:65-82.
25. Deugnier Y, Battistelli D, Jouanolle H, Guyader D, Gueguen M, Loreal O, et al. Hepatitis B virus infection markers in genetic haemochromatosis. A study of 272 patients. J Hepatol 1991;13:286-90.
26. Hann HW, Kim CY, London WT, Blumberg BS. Increased serum ferritin in chronic liver disease: a risk factor for primary hepatocellular carcinoma. Int J Cancer 1989;43:376-9.
27. Lin A, Yan WH, Xu HH, Zhu M, Zhou MY. Analysis of the HFE gene (C282Y, H63D and S65C) mutations in a general Chinese Han population. Tissue Antigens 2007;70:252-5.
28. Chang JG, Liu TC, Lin SF. Rapid diagnosis of the HLA-H gene Cys 282 Tyr mutation in hemochromatosis by polymerase chain reaction-avery rare mutation in the Chinese population. Blood 1997;89:3492-3.
29. Statistics by Country for Hemochromatosis. [cited April 10, 2014]; Available from: http://www.rightdiagnosis.com/h/hemochromatosis/stats-country.htm#extrapwarning.
30. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78.
31. Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011;26:131-7.
32. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106:148-55.
33. Huang X. Does iron have a role in breast cancer? Lancet Oncol 2008;9:803-7.
34. Kabat GC, Rohan TE. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control 2007;18:1047-53.
35. Kabat GC, Cross AJ, Park Y, Schatzkin A, Hollenbeck AR, Rohan TE, et al. Intakes of dietary iron and heme-iron and risk of postmenopausal breast cancer in the National Institutes of Health-AARP Diet and Health Study. Am J Clin Nutr 2010;92:1478-83.
36. Zeleniuch-Jacquotte A, Zhang Q, Dai J, Shore RE, Arslan AA, Koenig KL, et al. Reliability of serum assays of iron status in postmenopausal women. Ann Epidemiol 2007;17:354-8.
37. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and Cancer risk-a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomarkers Prev 2014;23:12-31.
38. Merk K, Mattsson B, Mattsson A, Holm G, Gullbring B, Bjorkholm M. The incidence of cancer among blood donors. Int J Epidemiol 1990;19:505-9.
39. Dale JC, Burritt MF, Zinsmeister AR. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol 2002;117:802-8.